Innovent receives fast track designation from FDA for IBI3003, a trispecific antibody for multiple myeloma. Jan. 26, 2026.
On January 26, 2026, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical firm based in San Francisco and Suzhou, China, specializes in the development, production, and distribution of top-tier medications. Their focus is on treating various conditions including oncologic, autoimmune, and cardiovascular diseases.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments